Newamsterdam Pharma Company N.V. - (NAMS) closed at $19.18 on November 10, 2026, up 0.9% from the previous close, on volume of 2,282,294 shares (30-day average 1,464,631).
Data as of November 10, 2026.
10-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 12, 2026 | Diagonal Double Call Spread | 16-Oct-2625 : 30 C|20-Nov-2622.5 : 25 C | 1,160 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Analysts’ Top Healthcare Picks: Edwards Lifesciences (EW), Helus Pharma (HELP)
TipRanks (Mon, 9-Nov 11:20 AM ET)
Piper Sandler Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)
TipRanks (Mon, 9-Nov 9:25 AM ET)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:01 PM ET)
TipRanks (Fri, 6-Nov 8:58 AM ET)
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
Globe Newswire (Wed, 4-Nov 7:30 AM ET)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in November
Globe Newswire (Tue, 3-Nov 8:00 AM ET)
Globe Newswire (Tue, 29-Sep 8:00 AM ET)
Globe Newswire (Mon, 21-Sep 9:00 AM ET)
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
Globe Newswire (Wed, 2-Sep 8:00 AM ET)
Globe Newswire (Wed, 26-Aug 8:00 AM ET)
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Newamsterdam Pharma Company N.V. - trades on the NASDAQ stock market under the symbol NAMS.
As of November 10, 2026, NAMS stock price climbed to $19.18 with 2,282,294 million shares trading.
NAMS has a beta of 1.36, meaning it tends to be more sensitive to market movements. NAMS has a correlation of 0.09 to the broad based SPY ETF.
NAMS has a market cap of $2.30 billion. This is considered a Mid Cap stock.
Last quarter Newamsterdam Pharma Company N.V. - reported $19 million in Revenue and -$.14 earnings per share. This beat revenue expectation by $12 million and exceeded earnings estimates by $.31.
In the last 3 years, NAMS traded as high as $42.21 and as low as $8.64.
The top ETF exchange traded funds that NAMS belongs to (by Net Assets): CGMM, IBB, VHT, SBIO, ESML.
NAMS has underperformed the market in the last year with a return of -47.8%, while the SPY ETF gained +12.9%. In the last 3 month period, NAMS fell short of the market, returning -31.4%, while SPY returned -2.8%. However, in the most recent 2 weeks NAMS has outperformed the stock market by returning -1.8%, while SPY returned -2.0%.
NAMS support price is $18.26 and resistance is $19.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NAMS shares will trade within this expected range on the day.
